Acquired by New Relic.
Sentea leverages silicon photonics to develop a cost-effective fiber optic sensor interrogator.
ABSCINT is developing single-domain antibodies for disease diagnosis through imaging.
Obulytix develops the next generation of enzyme-based antibiotics inspired by nature.
